Travere Therapeutics (TVTX) Gross Margin (2014 - 2026)
Travere Therapeutics' (TVTX) quarterly Gross Margin came in at 98.47% in Q1 2026, up 419.0% YoY from 18.97% in Q1 2025, and down 2.24% on a QoQ basis from 100.73% in Q4 2025.
Travere Therapeutics (TVTX) Gross Margin (2014 - 2026) Analysis & Trends
Travere Therapeutics (TVTX) has 13 years of Gross Margin data on file, last reported at 98.47% in Q1 2026.
- Quarterly Gross Margin rose 419.0% year-over-year to 98.47% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 110.86% (up 1485.0% YoY) and the FY2025 annual result came in at 11.17%, down 10785.0% from the prior year.
- Gross Margin declined to 98.47% in Q1 2026, from 100.73% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 100.73% in Q4 2025 to a low of 86.58% in Q1 2023.
- A 5-year average of 95.29% and a median of 96.19% in 2024 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2023 — Gross Margin plunged 717 bps — and 2024, when it soared 978 bps.
- Tracing TVTX's Gross Margin over 5 years: stood at 97.04% in 2022, then fell by 7 bps to 89.87% in 2023, then gained by 7 bps to 96.59% in 2024, then increased by 4 bps to 100.73% in 2025, then dropped by 2 bps to 98.47% in 2026.
- The last three Gross Margin figures came in at 98.47% (Q1 2026), 100.73% (Q4 2025), and 96.04% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 90.68% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 89.76% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 60,631,834.75% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 76.90% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 84.20% |
| 10 | Travere Therapeutics | 5.85 Bn | 5.85 Bn | 162.52 Mn | 95.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 95.84% |
| Mar 31, 2026 | 98.47% |
| Dec 31, 2025 | 100.73% |
| Sep 30, 2025 | 96.04% |
| Jun 30, 2025 | 98.67% |
| Mar 31, 2025 | 94.28% |
| Dec 31, 2024 | 96.59% |
| Sep 30, 2024 | 97.41% |
| Jun 30, 2024 | 96.19% |
| Mar 31, 2024 | 96.36% |
| Dec 31, 2023 | 89.87% |
| Sep 30, 2023 | 96.53% |
| Jun 30, 2023 | 95.49% |
| Mar 31, 2023 | 86.58% |
| Dec 31, 2022 | 97.04% |
| Sep 30, 2022 | 96.03% |
| Jun 30, 2022 | 92.84% |
| Mar 31, 2022 | 90.87% |
| Dec 31, 2021 | 99.32% |
| Sep 30, 2021 | 97.67% |